What have we lost in the wake of the rosiglitazone controversy?

Endocrine Practice

Volumn 15, Issue 3, 2009, Pages 273-274

  Zarich, Stuart W ^a   Nesto, Richard W ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DRUG WITHDRAWAL; EDITORIAL; FRACTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; METABOLISM; NOTE; RISK ASSESSMENT; RISK FACTOR; STATISTICS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 67649230846     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (8)

1. Fanning EL, Weissman PN, Menditto LA. Clinical practice effect of rosiglitazone on glycemic control. Endocr Pract. 2009;15:270-272.
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [erratum in N Engl J Med. 2007;357:100]. N Eng J Med. 2007;356:2457-2471.
3. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [erratum in N Engl J Med. 2007;356:1387-1388]. N Engl J Med. 2006;355:2427-2443.
4. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia. 2005;48:1726-1735.
5. Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360:129-139.
6. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive blood glucose lowering in type 2 diabetes. N Eng J Med. 2008;358:2545-2459.
7. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial [erratum in Lancet. 2006;368:1770]. Lancet. 2006;368:1096-1105.
8. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129-1136.